| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $6,452,284 | 135 | 100 |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 0 | $0 | 10 | $963,934 | $-963,934 |
| GADICKE ANSBERT | 10 percent owner | 0 | $0 | 23 | $1.51M | $-1.51M |
| MPM BioVentures 2014, L.P. | 10 percent owner | 0 | $0 | 23 | $1.51M | $-1.51M |
| EVNIN LUKE | director | 0 | $0 | 82 | $2.8M | $-2.8M |
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting …
Over the last 12 months, insiders at Werewolf Therapeutics, Inc. have bought $0 and sold $6.45M worth of Werewolf Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Werewolf Therapeutics, Inc. have bought $2.29M and sold $2.91M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 162,539 shares for transaction amount of $159,288 was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑05‑14.
| 2026-07-07 | Sale | EVNIN LUKE | director | 107,429 0.1992% | $0.31 | $33,303 | +168.95% | |
| 2026-07-06 | Sale | EVNIN LUKE | director | 35,770 0.0736% | $0.32 | $11,446 | +188.22% | |
| 2026-06-29 | Sale | EVNIN LUKE | director | 157,084 0.3002% | $0.30 | $47,125 | +198.73% | |
| 2026-06-17 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 416,911 0.8729% | $0.35 | $145,919 | +161.63% | |
| 2026-06-16 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 149,625 0.2929% | $0.37 | $55,361 | +147.22% | |
| 2026-06-15 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 128,770 0.2657% | $0.39 | $50,220 | +127.99% | |
| 2026-06-12 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 170,441 0.3682% | $0.40 | $68,176 | +131.84% | |
| 2026-06-11 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 262,503 0.5624% | $0.38 | $99,751 | +123.85% | |
| 2026-06-10 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 45,923 0.0958% | $0.37 | $16,992 | +141.51% | |
| 2026-06-09 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 369,800 0.7518% | $0.37 | $136,826 | +134.31% | |
| 2026-06-09 | Sale | EVNIN LUKE | director | 76,928 0.1564% | $0.37 | $28,463 | +134.31% | |
| 2026-06-08 | Sale | EVNIN LUKE | director | 60,547 0.127% | $0.40 | $24,219 | +128.72% | |
| 2026-06-05 | Sale | EVNIN LUKE | director | 24,946 0.0523% | $0.40 | $9,978 | +75.11% | |
| 2026-06-04 | Sale | EVNIN LUKE | director | 20,072 0.0423% | $0.44 | $8,832 | +16.37% | |
| 2026-06-03 | Sale | EVNIN LUKE | director | 29,749 0.0598% | $0.42 | $12,495 | +13.66% | |
| 2026-06-02 | Sale | EVNIN LUKE | director | 29,595 0.0637% | $0.45 | $13,318 | +6.95% | |
| 2026-06-01 | Sale | EVNIN LUKE | director | 80,459 0.167% | $0.47 | $37,816 | -2.01% | |
| 2026-05-29 | Sale | EVNIN LUKE | director | 32,556 0.0661% | $0.45 | $14,650 | +2.22% | |
| 2026-05-28 | Sale | EVNIN LUKE | director | 27,698 0.0575% | $0.46 | $12,741 | +0.14% | |
| 2026-05-27 | Sale | EVNIN LUKE | director | 80,852 0.163% | $0.48 | $38,809 | -6.94% |
| GADICKE ANSBERT | Former 10% Owner | 4784111 9.844% | $5.12M | 1 | 29 | <0.0001% |
| MPM BioVentures 2014, L.P. | Former 10% Owner | 4784111 9.844% | $5.12M | 1 | 29 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 303719 0.6249% | $324,979.33 | 8 | 10 | +4.98% |
| EVNIN LUKE | director | 0 0% | $0 | 2 | 88 | <0.0001% |
| Flynn James E | 10 percent owner | 2552787 5.2527% | $2.73M | 1 | 0 | <0.0001% |
| Asanuma Sakae | 2068909 4.2571% | $2.21M | 2 | 0 | <0.0001% | |
| Taiho Ventures LLC | 10 percent owner | 2068909 4.2571% | $2.21M | 1 | 0 | <0.0001% |
| Lazarus Alon | 2046634 4.2113% | $2.19M | 2 | 0 | <0.0001% | |
| Arkin Bio Ventures 2 L.P. | 10 percent owner | 2046634 4.2113% | $2.19M | 1 | 0 | <0.0001% |
| Longwood Fund III GP, LLC | 10 percent owner | 1677082 3.4508% | $1.79M | 1 | 0 | <0.0001% |
| Sphera Global Healthcare Management LP | 10 percent owner | 787997 1.6214% | $843,156.79 | 1 | 0 | <0.0001% |
$103,288,323 | 51 | 4.78% | $56.52M | |
$24,478,755 | 37 | -34.59% | $53.59M | |
$115,646,156 | 35 | 16.45% | $54.05M | |
$47,296,259 | 27 | 18.16% | $44.4M | |
$390,510 | 22 | 17.68% | $58.22M |
| Increased Positions | 23 | +28.05% | 1M | +5.59% |
| Decreased Positions | 34 | -41.46% | 3M | -14.86% |
| New Positions | 9 | New | 776,945 | New |
| Sold Out Positions | 16 | Sold Out | 732,728 | Sold Out |
| Total Postitions | 71 | -13.41% | 19M | -9.27% |
| Ra Capital Management, L.P. | $4,309.00 | 13.64% | 6.68M | 0 | 0% | 2025-09-30 |
| Mpm Asset Management Llc | $2,780.00 | 8.8% | 4.31M | 0 | 0% | 2025-09-30 |
| Mpm Bioimpact Llc | $1,554.00 | 4.92% | 2.41M | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,181.00 | 3.74% | 1.83M | -298,732 | -14.03% | 2025-09-30 |
| Vanguard Group Inc | $908.00 | 2.87% | 1.41M | +109,796 | +8.46% | 2025-09-30 |
| Sphera Funds Management Ltd. | $404.00 | 1.28% | 626,810 | 0 | 0% | 2025-09-30 |
| Dc Funds, Lp | $380.00 | 1.2% | 589,102 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $294.00 | 0.93% | 456,000 | +139,700 | +44.17% | 2025-09-30 |
| Pfm Health Sciences, Lp | $259.00 | 0.82% | 401,110 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $213.00 | 0.68% | 330,787 | +2,832 | +0.86% | 2025-09-30 |